273 related articles for article (PubMed ID: 32323921)
1. STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer.
Oberhuber M; Pecoraro M; Rusz M; Oberhuber G; Wieselberg M; Haslinger P; Gurnhofer E; Schlederer M; Limberger T; Lagger S; Pencik J; Kodajova P; Högler S; Stockmaier G; Grund-Gröschke S; Aberger F; Bolis M; Theurillat JP; Wiebringhaus R; Weiss T; Haitel A; Brehme M; Wadsak W; Griss J; Mohr T; Hofer A; Jäger A; Pollheimer J; Egger G; Koellensperger G; Mann M; Hantusch B; Kenner L
Mol Syst Biol; 2020 Apr; 16(4):e9247. PubMed ID: 32323921
[TBL] [Abstract][Full Text] [Related]
2. Ascites-derived ALDH+CD44+ tumour cell subsets endow stemness, metastasis and metabolic switch via PDK4-mediated STAT3/AKT/NF-κB/IL-8 signalling in ovarian cancer.
Jiang YX; Siu MK; Wang JJ; Mo XT; Leung TH; Chan DW; Cheung AN; Ngan HY; Chan KK
Br J Cancer; 2020 Jul; 123(2):275-287. PubMed ID: 32390009
[TBL] [Abstract][Full Text] [Related]
3. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
4. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
5. Asporin is a stromally expressed marker associated with prostate cancer progression.
Rochette A; Boufaied N; Scarlata E; Hamel L; Brimo F; Whitaker HC; Ramos-Montoya A; Neal DE; Dragomir A; Aprikian A; Chevalier S; Thomson AA
Br J Cancer; 2017 Mar; 116(6):775-784. PubMed ID: 28152543
[TBL] [Abstract][Full Text] [Related]
6. Integrated Analysis Revealed Prognostic Factors for Prostate Cancer Patients.
Che H; Liu Y; Zhang M; Meng J; Feng X; Zhou J; Liang C
Med Sci Monit; 2019 Dec; 25():9991-10007. PubMed ID: 31876269
[TBL] [Abstract][Full Text] [Related]
7. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
Kulda V; Topolcan O; Kucera R; Kripnerova M; Srbecka K; Hora M; Hes O; Klecka J; Babuska V; Rousarova M; Benson V; Pesta M
Anticancer Res; 2016 Sep; 36(9):4787-93. PubMed ID: 27630329
[TBL] [Abstract][Full Text] [Related]
9. Random forest-based modelling to detect biomarkers for prostate cancer progression.
Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
[TBL] [Abstract][Full Text] [Related]
10. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
11. Association of High miR-182 Levels with Low-Risk Prostate Cancer.
Baumann B; Acosta AM; Richards Z; Deaton R; Sapatynska A; Murphy A; Kajdacsy-Balla A; Gann PH; Nonn L
Am J Pathol; 2019 Apr; 189(4):911-923. PubMed ID: 30703341
[TBL] [Abstract][Full Text] [Related]
12. Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness.
Piao XM; Byun YJ; Jeong P; Ha YS; Yoo ES; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2017 Aug; 15(4):450-454. PubMed ID: 27842896
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
15. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
[TBL] [Abstract][Full Text] [Related]
16. Ursolic acid inhibits multiple cell survival pathways leading to suppression of growth of prostate cancer xenograft in nude mice.
Shanmugam MK; Rajendran P; Li F; Nema T; Vali S; Abbasi T; Kapoor S; Sharma A; Kumar AP; Ho PC; Hui KM; Sethi G
J Mol Med (Berl); 2011 Jul; 89(7):713-27. PubMed ID: 21465181
[TBL] [Abstract][Full Text] [Related]
17. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the novel senescence marker β-galactosidase (GLB1) in prostate cancer predicts reduced PSA recurrence.
Wagner J; Damaschke N; Yang B; Truong M; Guenther C; McCormick J; Huang W; Jarrard D
PLoS One; 2015; 10(4):e0124366. PubMed ID: 25876105
[TBL] [Abstract][Full Text] [Related]
19. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
20. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
